A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy

Inclusion Criteria:

- Confirmed diagnosis of CD for at least 3 months prior to Baseline.

- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),
abdominal pain (AP) score.

- Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's
disease (SES-CD) on an endoscopy confirmed by a central reader.

- Demonstrated an inadequate response or intolerance to conventional therapies (Oral
locally acting steroids, Intravenous or oral corticosteroids, Immunosuppressants), in
the opinion of the investigator.

Note: Participants who have received prior biologic may be enrolled; however, participants
must have discontinued the biologic for reasons other than inadequate response or
intolerance (e.g., change of insurance, well controlled disease),

- If female, subject must meet the contraception recommendations.

Exclusion Criteria:

- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.

- Participant not on stable doses of CD related antibiotics, oral aminosalicylates,
corticosteroids or methotrexate (MTX).

- Participant with the following known complications of CD: abscess (abdominal or
peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, or any
other manifestation that might require surgery while enrolled in the study.

- Participant with ostomy or ileoanal pouch

- Participant diagnosed with short gut or short bowel syndrome

- Screening laboratory and other analyses show abnormal results.